Physicians' Academy for Cardiovascular Education

Innovations in lipid management: Evolving insights and implications from PCSK9 research

Aug. 30, 2014

View lectures

 

PCSK9: The promise of a new target in lipid management

Prof. John E Deanfield, London introducing the rationale for PCSK9 inhibition with a lecture held during an EBAC accredited symposium on innovations in lipid management at ESC 2014 in Barcelona
 

Biology and validation of PCSK9 as a novel target to lower LDL-C

Lecture by Prof. John Kastelein, Amsterdam, The Netherlands, held during EBAC accredited symposium 'Managing Innovations in lipid management: Evolving insights and implications from PCSK9 research
 

PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

Lecture by Prof. Evan Stein, Cincinnati, OH, USA held during EBAC accredited symposium 'Innovations in lipid management: Evolving insights and implications from PCSK9 research'
 

Critique on the new AHA / ACC guidelines for lipid management

Lecture by Prof. Kausik Ray, London, United Kingdom, held during EBAC accredited symposium ' Managing Innovations in lipid management:

 

Presentations (to view & download in PDF) presented during the symposium

PCSK9: The promise of a new target in lipid management

Presentation by prof. John Deanfield, MD, London
 


Biology and validation of PCSK9 as a novel target to lower LDL-C

Presentation by prof. John Kastelein, MD, Amsterdam
 
 
PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga

Presentation by prof. Evan Stein, MD, Cincinnati, OH, USA 



Critique on the new AHA / ACC guidelines for lipid management
Presentation by prof. Kausik Ray, MD, London
 


Educational objectives of the symposium:

  • Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients with FH
  • Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
  • Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
  • Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
  • Understand the implications of new guidelines for lipid management


Educational Agenda


Introduction - PCSK9: The promise of a new target in lipid management
John Deanfield,  University College London, London, United Kingdom

Biology and validation of PCSK9 as a novel target to lower LDL-C 
John Kastelein, Academic Medical Center, Amsterdam, Netherlands
 
PCSK9 inhibition: Novel insights into a new therapeutic approach for the lowering of LDL-C: the PCSK9 saga
Evan Stein, Metabolic and Atherosclerosis Research Center, Cincinnati, USA
 
Critique on the new AHA/ACC guidelines for lipid management
Kausik Ray, St George’s Hospital NHS Trust, London, United Kingdom
 
Discussion & summary
John Kastelein, John Deanfield


CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have  actually been spent in the educational activity. EBAC works according to the quality standards the European Accreditation for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS)
 

Financial support

Supported by unrestricted educational grants from Amgen, Regeneron/Sanofi, Pfizer, Lilly